AU2008322676B9 - Pyridazinone derivatives as PARP inhibitors - Google Patents

Pyridazinone derivatives as PARP inhibitors Download PDF

Info

Publication number
AU2008322676B9
AU2008322676B9 AU2008322676A AU2008322676A AU2008322676B9 AU 2008322676 B9 AU2008322676 B9 AU 2008322676B9 AU 2008322676 A AU2008322676 A AU 2008322676A AU 2008322676 A AU2008322676 A AU 2008322676A AU 2008322676 B9 AU2008322676 B9 AU 2008322676B9
Authority
AU
Australia
Prior art keywords
oxo
carbonyl
oxopiperazin
dihydropyridazin
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008322676A
Other languages
English (en)
Other versions
AU2008322676A1 (en
AU2008322676B2 (en
Inventor
Danila Branca
Gabriella Dessole
Federica Ferrigno
Philip Jones
Olaf Kinzel
Samuele Lillini
Ester Muraglia
Giovanna Pescatore
Carsten Schultz-Fademrecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD Italia SRL
Original Assignee
MSD Italia SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0722401A external-priority patent/GB0722401D0/en
Priority claimed from GB0816707A external-priority patent/GB0816707D0/en
Application filed by MSD Italia SRL filed Critical MSD Italia SRL
Publication of AU2008322676A1 publication Critical patent/AU2008322676A1/en
Application granted granted Critical
Publication of AU2008322676B2 publication Critical patent/AU2008322676B2/en
Publication of AU2008322676B9 publication Critical patent/AU2008322676B9/en
Assigned to MSD ITALIA S.R.L. reassignment MSD ITALIA S.R.L. Request for Assignment Assignors: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2008322676A 2007-11-15 2008-11-14 Pyridazinone derivatives as PARP inhibitors Active AU2008322676B9 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0722401.7 2007-11-15
GB0722401A GB0722401D0 (en) 2007-11-15 2007-11-15 Therapeutic compounds
GB0816707A GB0816707D0 (en) 2008-09-12 2008-09-12 Therapeutic compounds
GB0816707.4 2008-09-12
PCT/GB2008/051063 WO2009063244A1 (en) 2007-11-15 2008-11-14 Pyridazinone derivatives as parp inhibitors

Publications (3)

Publication Number Publication Date
AU2008322676A1 AU2008322676A1 (en) 2009-05-22
AU2008322676B2 AU2008322676B2 (en) 2013-12-05
AU2008322676B9 true AU2008322676B9 (en) 2014-03-27

Family

ID=40427149

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008322676A Active AU2008322676B9 (en) 2007-11-15 2008-11-14 Pyridazinone derivatives as PARP inhibitors

Country Status (14)

Country Link
US (1) US8268827B2 (enExample)
EP (1) EP2220073B1 (enExample)
JP (1) JP5758630B2 (enExample)
KR (1) KR101641596B1 (enExample)
CN (1) CN101855221B (enExample)
AU (1) AU2008322676B9 (enExample)
CA (1) CA2704714C (enExample)
ES (1) ES2524787T3 (enExample)
IL (1) IL205142A (enExample)
MX (1) MX2010005070A (enExample)
NZ (1) NZ585395A (enExample)
RU (1) RU2490265C2 (enExample)
WO (1) WO2009063244A1 (enExample)
ZA (1) ZA201002466B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822476B2 (en) * 2009-04-02 2014-09-02 Merck Patent Gmbh Piperidine and piperazine derivatives as autotaxin inhibitors
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US9090568B2 (en) * 2011-03-14 2015-07-28 Impact Therapeutics, Inc. Quinazolinediones and their use
ES2871052T3 (es) 2011-05-31 2021-10-28 Rakovina Therapeutics Inc Inhibidores tricíclicos de la poli(ADP-ribosa)polimerasa
US9328111B2 (en) 2011-12-31 2016-05-03 Beigene Ltd. Substituted cycloocta[5,6]pyrido[4,3,2-de]phthalazines as PARP inhibitors
SI2797921T1 (en) 2011-12-31 2018-01-31 Beigene, Ltd. Condensed tetra- or pentacyclic dihydrodiazepinocarbazolones as PARP inhibitors
KR20220137154A (ko) 2012-01-20 2022-10-11 데니스 엠. 브라운 다형교모세포종 및 수모세포종을 비롯한 신생종양 질환 및 암 줄기세포의 치료를 위한 디안히드로갈락티톨 및 유사체를 비롯한 치환된 헥시톨의 용도
SG11201408679XA (en) 2012-06-26 2015-01-29 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CN103570725B (zh) * 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
MA38080A1 (fr) * 2012-12-31 2018-02-28 Cadila Healthcare Ltd Dérivés substitués de phtalazin-1(2h)-one comme inhibiteurs sélectifs de la poly(adp-ribose) polymérase-1
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
KR20160104612A (ko) 2013-07-26 2016-09-05 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조성물
KR101670126B1 (ko) 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
AU2015240465B2 (en) 2014-04-04 2020-02-27 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
FR3027901B1 (fr) * 2014-10-31 2018-03-16 Universite De Reims Champagne Ardenne Nouveaux procedes appartenant a la famille des pyridazinones.
EP3233840B1 (en) 2014-12-16 2018-11-21 Eudendron S.r.l. Heterocyclic derivatives modulating activity of certain protein kinases
US10106501B2 (en) * 2015-06-09 2018-10-23 Abbvie Inc. Nuclear receptor modulators
EA033679B1 (ru) * 2015-09-02 2019-11-15 Glaxosmithkline Ip No 2 Ltd Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
US10246469B2 (en) 2015-10-01 2019-04-02 Bristol-Myers Squibb Company Biaryl kinase inhibitors
KR102030016B1 (ko) 2016-09-05 2019-10-08 충남대학교산학협력단 신규한 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물
KR102007135B1 (ko) 2017-03-20 2019-08-02 포르마 세라퓨틱스 인크. 피루베이트 키나제 (pkr) 활성화제로서의 피롤로피롤 조성물
CN108383837B (zh) * 2018-02-09 2020-08-11 福建医科大学 一种氨基取代四氢吡啶并嘧啶类化合物或其可用盐及其制备方法与应用
WO2019212946A1 (en) 2018-04-30 2019-11-07 Ribon Therapeutics Inc. Screening methods for parp modulators
HUE062096T2 (hu) * 2018-04-30 2023-09-28 Ribon Therapeutics Inc Piridazinonok PARP7-inhibitorokként
KR102017115B1 (ko) 2018-05-15 2019-09-02 충남대학교산학협력단 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
US12371421B2 (en) 2019-04-29 2025-07-29 Ribon Therapeutics, Inc. Solid forms of a PARP7 inhibitor
CN110818908B (zh) * 2019-08-29 2021-12-17 杭州市富阳区浙工大银湖创新创业研究院 一种用于检测氧化气体的金属有机骨架材料的制备方法
US20220378756A1 (en) 2019-09-19 2022-12-01 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20240190844A1 (en) * 2019-10-30 2024-06-13 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
AU2020375821A1 (en) 2019-10-30 2022-06-02 Ribon Therapeutics, Inc. Pyridazinones as PARP7 inhibitors
CA3158807A1 (en) 2019-10-30 2021-05-06 Digmbio. Inc. Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(adp-ribose) polymerase-1-related diseases, comprising the same as active ingredient
EP4139298A4 (en) 2020-04-21 2024-05-22 Idience Co., Ltd. Process for preparing a phthalazinone derivative and intermediates thereof
AU2020444056A1 (en) 2020-04-21 2022-11-17 Idience Co., Ltd. Crystalline forms of phthalazinone compound
WO2021224186A1 (en) * 2020-05-04 2021-11-11 Institut Curie New pyridine derivatives as radiosensitizers
US12059419B2 (en) 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
CN117425648A (zh) * 2021-03-12 2024-01-19 杭州英创医药科技有限公司 作为parp7抑制剂的化合物
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CA3212583A1 (en) 2021-03-27 2022-10-06 Daniel Gooding Compositions having improved bioavailability of therapeutics
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药（上海）有限公司 作为parp7抑制剂的哒嗪酮类化合物
CN117751108A (zh) * 2021-07-21 2024-03-22 南京明德新药研发有限公司 哒嗪酮类化合物
JP2024528021A (ja) * 2021-07-29 2024-07-26 上海齊魯制藥研究中心有限公司 新規なｐａｒｐ７阻害剤及びその使用
CN117279907A (zh) * 2021-08-06 2023-12-22 成都百裕制药股份有限公司 吡咯烷酮衍生物及其在医药上的应用
CA3234909A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CN115745971B (zh) * 2021-12-20 2024-07-30 北京华森英诺生物科技有限公司 Parp7抑制剂及其应用
CN116375688B (zh) * 2021-12-23 2025-04-11 中国药科大学 哒嗪酮类化合物及其制备方法、药物组合物和应用
CA3245873A1 (en) * 2022-03-14 2023-09-21 Trx Biosciences Ltd Compositions with improved bioavailability of therapeutic agents and their uses
JP7763538B2 (ja) * 2022-04-01 2025-11-04 諾沃斯達薬業（上海）有限公司 Ｐａｒｐ７阻害剤及びその使用
JP2025534359A (ja) * 2022-09-30 2025-10-15 アズカラ セラピューティクス インク ピリダジン－３（２ｈ）－オンおよびピリジン－２（１ｈ）－オンのＰＡＲＰ阻害化合物
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025087383A1 (zh) * 2023-10-26 2025-05-01 深圳众格生物科技有限公司 作为parp7抑制剂的化合物
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007138351A2 (en) * 2006-05-31 2007-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
IL118631A (en) * 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
CN1136197C (zh) * 1996-05-30 2004-01-28 霍夫曼-拉罗奇有限公司 新的哒嗪酮衍生物
KR100804564B1 (ko) 2000-10-30 2008-02-20 쿠도스 파마슈티칼스 리미티드 프탈라지논 유도체
EP1397350B1 (en) 2001-05-08 2007-02-28 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
ES2357057T3 (es) 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited Derivados de ftalazinona.
KR101146806B1 (ko) 2003-03-12 2012-05-22 메이브릿지 리미티드 프탈라지논 유도체
MXPA05010081A (es) * 2003-03-24 2005-11-23 Hoffmann La Roche Bencil-piridazinonas como inhibidores de transcriptasa inversa.
MXPA06009701A (es) 2004-02-26 2007-03-26 Inotek Pharmaceuticals Corp Derivados de isoquinolina y metodos de uso de los mismos.
JP4627315B2 (ja) 2004-03-23 2011-02-09 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤としてのベンジルピリダジノン誘導体
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
JP2007532592A (ja) * 2004-04-15 2007-11-15 エフ．ホフマン−ラ　ロシュ　アーゲー ピリダジノン化合物の製造方法
WO2006021801A1 (en) 2004-08-26 2006-03-02 Kudos Pharmaceuticals Limited 4-heteroarylmethyl substituted phthalazinone derivatives
HRP20100633T1 (hr) 2005-07-21 2011-01-31 F. Hoffmann - La Roche Ag Derivati piridazinona kao agonisti receptora tiroidnih hormona
PH12012501544A1 (en) * 2006-12-28 2024-06-03 Abbvie Inc Inhibitors of poly (adp-ribose) polymerase
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
US20080280910A1 (en) 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007138351A2 (en) * 2006-05-31 2007-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp)

Also Published As

Publication number Publication date
ZA201002466B (en) 2010-12-29
IL205142A0 (en) 2010-11-30
US20100261709A1 (en) 2010-10-14
CN101855221A (zh) 2010-10-06
ES2524787T3 (es) 2014-12-12
RU2490265C2 (ru) 2013-08-20
KR20100087220A (ko) 2010-08-03
US8268827B2 (en) 2012-09-18
JP5758630B2 (ja) 2015-08-05
AU2008322676A1 (en) 2009-05-22
WO2009063244A1 (en) 2009-05-22
EP2220073A1 (en) 2010-08-25
JP2011503166A (ja) 2011-01-27
CA2704714A1 (en) 2009-05-22
BRPI0820236A2 (pt) 2015-06-16
MX2010005070A (es) 2010-05-24
RU2010123874A (ru) 2011-12-20
CA2704714C (en) 2018-12-04
CN101855221B (zh) 2013-10-30
KR101641596B1 (ko) 2016-07-21
NZ585395A (en) 2012-03-30
IL205142A (en) 2014-09-30
AU2008322676B2 (en) 2013-12-05
EP2220073B1 (en) 2014-09-03

Similar Documents

Publication Publication Date Title
AU2008322676B9 (en) Pyridazinone derivatives as PARP inhibitors
AU2008204380B2 (en) Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
EP2029551B1 (en) Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
US8436185B2 (en) Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
US8354413B2 (en) Quinolin-4-one and 4-oxodihydrocinnoline derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP)
AU2009224004A1 (en) Tricyclic derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP)
NZ578256A (en) Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
AU2007283212A1 (en) 4-oxo-4,5-dihydropyrrolo[1,2-A] quinoxaline derivatives as inhibitors of poly(ADP-ribose)polymerase(PARP)
BRPI0820236B1 (pt) Compostos derivados de piridazinona, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos
HK40006670A (en) Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
HK1131137B (en) Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
HK1154386B (en) Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: MSD ITALIA S.R.L.

Free format text: FORMER OWNER WAS: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A.